AG˹ٷ

STOCK TITAN

[8-K] Intensity Therapeutics, Inc. Common stock Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

IQSTEL (IQST) PRE 14C: Via written consent, holders of 51.7 % of the voting stock approved amending the Articles of Incorporation to raise authorized common shares to 26,000,000 from 3,750,000 and total capital to 26.2 M. The change becomes effective 20 days after this statement is mailed; no meeting or dissenter rights apply.

Rationale: 897,238 shares are already reserved for outstanding convertibles; up to 93,000 may be issued for Globetopper EBITDA milestones; the board also cites growth capital, equity compensation and future M&A. A non-binding MOU with Cycurion (CYCU) envisions a reciprocal $1 M stock exchange that would require 109,770 new IQST shares (3.0 % post-issue stake) and grant IQST 5.9 % of CYCU.

The amendment grants the board broad discretion to issue additional stock without further shareholder approval, which could dilute current ownership and strengthen the company’s anti-takeover position. Estimated filing and mailing cost: $10,000.

IQSTEL (IQST) PRE 14C: Con il consenso scritto, i detentori del 51,7% delle azioni con diritto di voto hanno approvato la modifica dello Statuto per aumentare le azioni comuni autorizzate da 3.750.000 a 26.000.000 e il capitale totale a 26,2 milioni. La modifica diventerà effettiva 20 giorni dopo l'invio di questa comunicazione; non si applicano riunioni né diritti di dissenso.

Motivazione: 897.238 azioni sono già riservate per convertibili in circolazione; fino a 93.000 potrebbero essere emesse per il raggiungimento di obiettivi EBITDA di Globetopper; il consiglio cita inoltre capitale per la crescita, compensi azionari e future operazioni di fusione e acquisizione. Un protocollo d'intesa non vincolante con Cycurion (CYCU) prevede uno scambio reciproco di azioni del valore di 1 milione di dollari che richiederebbe 109.770 nuove azioni IQST (una partecipazione post-emissione del 3,0%) e concederebbe a IQST il 5,9% di CYCU.

La modifica concede al consiglio ampi poteri per emettere ulteriori azioni senza necessità di ulteriori approvazioni degli azionisti, il che potrebbe diluire la proprietà attuale e rafforzare la posizione anti-OPA della società. Costo stimato per deposito e invio: 10.000 dollari.

IQSTEL (IQST) PRE 14C: Mediante consentimiento por escrito, los titulares del 51,7 % de las acciones con derecho a voto aprobaron la modificación de los Estatutos para aumentar las acciones comunes autorizadas de 3.750.000 a 26.000.000 y el capital total a 26,2 millones. El cambio entrará en vigor 20 días después del envío de esta declaración; no se aplican reuniones ni derechos de disenso.

Razonamiento: 897.238 acciones ya están reservadas para convertibles en circulación; hasta 93.000 pueden emitirse por hitos de EBITDA de Globetopper; la junta también menciona capital para crecimiento, compensación accionaria y futuras fusiones y adquisiciones. Un memorando de entendimiento no vinculante con Cycurion (CYCU) contempla un intercambio recíproco de acciones por valor de 1 millón de dólares que requeriría 109.770 nuevas acciones de IQST (una participación posterior a la emisión del 3,0 %) y otorgaría a IQST el 5,9 % de CYCU.

La enmienda otorga a la junta amplia discreción para emitir acciones adicionales sin más aprobación de los accionistas, lo que podría diluir la propiedad actual y fortalecer la posición anti-adquisición de la compañía. Costo estimado de presentación y envío: 10.000 dólares.

IQSTEL (IQST) PRE 14C: 서면 동의� 통해 의결� 주식� 51.7% 보유자가 정관� 수정하여 승인 주식수를 3,750,000주에� 26,000,000주로, � 자본금을 2,620� 달러� 증액하는 안을 승인했습니다. � 변� 사항은 � 성명� 우편 발송� � 20� 후에 효력� 발생하며, 회의 개최� 반대권은 적용되지 않습니다.

배경: 897,238주는 이미 전환 가� 주식으로 예약되어 있으�, Globetopper EBITDA 목표 달성� 위해 최대 93,000주가 발행� � 있습니다. 이사회는 또한 성장 자본, 주식 보상 � 향후 인수합병 자금� 언급했습니다. Cycurion(CYCU)과의 구속� 없는 양해각서(MOU)� 상호 100� 달러 상당� 주식 교환� 계획하고 있으�, 이는 109,770주의 신규 IQST 주식(발행 � 지� 3.0%)� 필요� 하고 IQST에게 CYCU 지� 5.9%� 부여합니다.

이번 정관 수정은 이사회에 추가 주식� 주주 승인 없이 발행� � 있는 광범위한 재량권을 부여하� 현재 소유� 희석� 회사� 적대� 인수 방어� 강화가 예상됩니�. 제출 � 우편 발송 예상 비용은 10,000달러입니�.

IQSTEL (IQST) PRE 14C : Par consentement écrit, les détenteurs de 51,7 % des actions avec droit de vote ont approuvé la modification des statuts pour augmenter les actions ordinaires autorisées de 3 750 000 à 26 000 000 et le capital total à 26,2 millions. La modification prendra effet 20 jours après l'envoi de cette déclaration ; aucune réunion ni droit de dissidence ne s'applique.

Justification : 897 238 actions sont déjà réservées pour des titres convertibles en circulation ; jusqu'à 93 000 peuvent être émises en fonction des objectifs d'EBITDA de Globetopper ; le conseil mentionne également le capital de croissance, la rémunération en actions et les futures fusions-acquisitions. Un protocole d'accord non contraignant avec Cycurion (CYCU) prévoit un échange d'actions réciproque d'une valeur de 1 million de dollars, nécessitant 109 770 nouvelles actions IQST (une participation post-émission de 3,0 %) et accordant à IQST 5,9 % de CYCU.

L'amendement accorde au conseil une large discrétion pour émettre des actions supplémentaires sans approbation supplémentaire des actionnaires, ce qui pourrait diluer la propriété actuelle et renforcer la position anti-OPA de la société. Coût estimé de dépôt et d'envoi : 10 000 dollars.

IQSTEL (IQST) PRE 14C: Durch schriftliche Zustimmung haben Inhaber von 51,7 % der stimmberechtigten Aktien die Änderung der Satzung genehmigt, um die genehmigten Stammaktien von 3.750.000 auf 26.000.000 und das Gesamtkapital auf 26,2 Mio. zu erhöhen. Die Änderung wird 20 Tage nach Versand dieser Mitteilung wirksam; keine Versammlung oder Widerspruchsrechte gelten.

Begründung: 897.238 Aktien sind bereits für ausstehende Wandelanleihen reserviert; bis zu 93.000 können für Globetopper-EBITDA-Meilensteine ausgegeben werden; der Vorstand nennt außerdem Wachstumskapital, Aktienvergütung und zukünftige Fusionen und Übernahmen. Ein unverbindliches Memorandum of Understanding mit Cycurion (CYCU) sieht einen gegenseitigen Aktientausch im Wert von 1 Mio. USD vor, der 109.770 neue IQST-Aktien (3,0 % Anteil nach Ausgabe) erfordern und IQST 5,9 % von CYCU gewähren würde.

Die Änderung gewährt dem Vorstand weitreichenden Ermessensspielraum zur Ausgabe zusätzlicher Aktien ohne weitere Aktionärszustimmung, was die derzeitigen Eigentumsverhältnisse verwässern und die Anti-Übernahme-Position des Unternehmens stärken könnte. Geschätzte Kosten für Einreichung und Versand: 10.000 USD.

Positive
  • Strategic flexibility: Authorization rises to 26 M shares, enabling financing, acquisitions and equity incentives without further votes.
  • Potential Cycurion alliance: $1 M reciprocal stock exchange could open cross-selling between telecom, fintech and cybersecurity markets.
Negative
  • Dilution risk: Authorized share count grows 7×; current holders could see ownership fall materially if shares are issued.
  • Non-binding MOU: Cycurion deal may not close, yet shares are being authorized partly for that purpose.
  • Anti-takeover effect: Additional shares can be used to block hostile bids, reducing shareholder influence.

Insights

TL;DR: Big jump in authorized shares gives IQSTEL financing flexibility but heightens dilution risk.

The 593 % increase in authorized common shares equips management to fund growth, complete the Cycurion swap and cover existing commitments. Post-swap, Cycurion would own 3.0 % of IQST while IQST gains 5.9 % of CYCU, adding strategic cybersecurity exposure. However, with only 3.5 M shares outstanding today, shareholders face heavy potential dilution if the full 26 M authorization is used. No guidance on pricing or timing of issuances is provided. Near-term cash impact is minimal, but valuation could compress if new equity is issued below the current $9.11 close.

TL;DR: Amendment centralizes power; easier capital raises, tougher takeovers.

Written-consent approval sidesteps a meeting and installs ample "dry powder" for management. Because Nevada law allows issuance without further votes, insiders can deter hostile bids or steer friendly deals. Anti-takeover effect is explicit: extra shares can be placed strategically to block control changes. Investors should weigh governance concerns against the strategic upside of greater capital flexibility.

IQSTEL (IQST) PRE 14C: Con il consenso scritto, i detentori del 51,7% delle azioni con diritto di voto hanno approvato la modifica dello Statuto per aumentare le azioni comuni autorizzate da 3.750.000 a 26.000.000 e il capitale totale a 26,2 milioni. La modifica diventerà effettiva 20 giorni dopo l'invio di questa comunicazione; non si applicano riunioni né diritti di dissenso.

Motivazione: 897.238 azioni sono già riservate per convertibili in circolazione; fino a 93.000 potrebbero essere emesse per il raggiungimento di obiettivi EBITDA di Globetopper; il consiglio cita inoltre capitale per la crescita, compensi azionari e future operazioni di fusione e acquisizione. Un protocollo d'intesa non vincolante con Cycurion (CYCU) prevede uno scambio reciproco di azioni del valore di 1 milione di dollari che richiederebbe 109.770 nuove azioni IQST (una partecipazione post-emissione del 3,0%) e concederebbe a IQST il 5,9% di CYCU.

La modifica concede al consiglio ampi poteri per emettere ulteriori azioni senza necessità di ulteriori approvazioni degli azionisti, il che potrebbe diluire la proprietà attuale e rafforzare la posizione anti-OPA della società. Costo stimato per deposito e invio: 10.000 dollari.

IQSTEL (IQST) PRE 14C: Mediante consentimiento por escrito, los titulares del 51,7 % de las acciones con derecho a voto aprobaron la modificación de los Estatutos para aumentar las acciones comunes autorizadas de 3.750.000 a 26.000.000 y el capital total a 26,2 millones. El cambio entrará en vigor 20 días después del envío de esta declaración; no se aplican reuniones ni derechos de disenso.

Razonamiento: 897.238 acciones ya están reservadas para convertibles en circulación; hasta 93.000 pueden emitirse por hitos de EBITDA de Globetopper; la junta también menciona capital para crecimiento, compensación accionaria y futuras fusiones y adquisiciones. Un memorando de entendimiento no vinculante con Cycurion (CYCU) contempla un intercambio recíproco de acciones por valor de 1 millón de dólares que requeriría 109.770 nuevas acciones de IQST (una participación posterior a la emisión del 3,0 %) y otorgaría a IQST el 5,9 % de CYCU.

La enmienda otorga a la junta amplia discreción para emitir acciones adicionales sin más aprobación de los accionistas, lo que podría diluir la propiedad actual y fortalecer la posición anti-adquisición de la compañía. Costo estimado de presentación y envío: 10.000 dólares.

IQSTEL (IQST) PRE 14C: 서면 동의� 통해 의결� 주식� 51.7% 보유자가 정관� 수정하여 승인 주식수를 3,750,000주에� 26,000,000주로, � 자본금을 2,620� 달러� 증액하는 안을 승인했습니다. � 변� 사항은 � 성명� 우편 발송� � 20� 후에 효력� 발생하며, 회의 개최� 반대권은 적용되지 않습니다.

배경: 897,238주는 이미 전환 가� 주식으로 예약되어 있으�, Globetopper EBITDA 목표 달성� 위해 최대 93,000주가 발행� � 있습니다. 이사회는 또한 성장 자본, 주식 보상 � 향후 인수합병 자금� 언급했습니다. Cycurion(CYCU)과의 구속� 없는 양해각서(MOU)� 상호 100� 달러 상당� 주식 교환� 계획하고 있으�, 이는 109,770주의 신규 IQST 주식(발행 � 지� 3.0%)� 필요� 하고 IQST에게 CYCU 지� 5.9%� 부여합니다.

이번 정관 수정은 이사회에 추가 주식� 주주 승인 없이 발행� � 있는 광범위한 재량권을 부여하� 현재 소유� 희석� 회사� 적대� 인수 방어� 강화가 예상됩니�. 제출 � 우편 발송 예상 비용은 10,000달러입니�.

IQSTEL (IQST) PRE 14C : Par consentement écrit, les détenteurs de 51,7 % des actions avec droit de vote ont approuvé la modification des statuts pour augmenter les actions ordinaires autorisées de 3 750 000 à 26 000 000 et le capital total à 26,2 millions. La modification prendra effet 20 jours après l'envoi de cette déclaration ; aucune réunion ni droit de dissidence ne s'applique.

Justification : 897 238 actions sont déjà réservées pour des titres convertibles en circulation ; jusqu'à 93 000 peuvent être émises en fonction des objectifs d'EBITDA de Globetopper ; le conseil mentionne également le capital de croissance, la rémunération en actions et les futures fusions-acquisitions. Un protocole d'accord non contraignant avec Cycurion (CYCU) prévoit un échange d'actions réciproque d'une valeur de 1 million de dollars, nécessitant 109 770 nouvelles actions IQST (une participation post-émission de 3,0 %) et accordant à IQST 5,9 % de CYCU.

L'amendement accorde au conseil une large discrétion pour émettre des actions supplémentaires sans approbation supplémentaire des actionnaires, ce qui pourrait diluer la propriété actuelle et renforcer la position anti-OPA de la société. Coût estimé de dépôt et d'envoi : 10 000 dollars.

IQSTEL (IQST) PRE 14C: Durch schriftliche Zustimmung haben Inhaber von 51,7 % der stimmberechtigten Aktien die Änderung der Satzung genehmigt, um die genehmigten Stammaktien von 3.750.000 auf 26.000.000 und das Gesamtkapital auf 26,2 Mio. zu erhöhen. Die Änderung wird 20 Tage nach Versand dieser Mitteilung wirksam; keine Versammlung oder Widerspruchsrechte gelten.

Begründung: 897.238 Aktien sind bereits für ausstehende Wandelanleihen reserviert; bis zu 93.000 können für Globetopper-EBITDA-Meilensteine ausgegeben werden; der Vorstand nennt außerdem Wachstumskapital, Aktienvergütung und zukünftige Fusionen und Übernahmen. Ein unverbindliches Memorandum of Understanding mit Cycurion (CYCU) sieht einen gegenseitigen Aktientausch im Wert von 1 Mio. USD vor, der 109.770 neue IQST-Aktien (3,0 % Anteil nach Ausgabe) erfordern und IQST 5,9 % von CYCU gewähren würde.

Die Änderung gewährt dem Vorstand weitreichenden Ermessensspielraum zur Ausgabe zusätzlicher Aktien ohne weitere Aktionärszustimmung, was die derzeitigen Eigentumsverhältnisse verwässern und die Anti-Übernahme-Position des Unternehmens stärken könnte. Geschätzte Kosten für Einreichung und Versand: 10.000 USD.

0001567264FALSE00015672642025-08-072025-08-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 7, 2025
Intensity Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware001-4110946-1488089
(State or Other Jurisdiction
of Incorporation)
(Commission File Number) (IRS Employer
Identification No.)
1 Enterprise Drive, Suite 430
Shelton, CT
06484-4779
(Address of Principal Executive Offices)(Zip Code)
(203) 221-7381
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class:Trading Symbol(s):Name of Exchange on Which Registered:
Common Stock, $0.0001 par value per shareINTSThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02 Results of Operations and Financial Condition.
On August 7, 2025, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three and six months ended June 30, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.
The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1
Press Release issued August 7, 2025.
104Cover Page Interactive Data File (formatted in Inline XBRL).
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Comments in this Current Report on Form 8-K and in the exhibit attached hereto contain certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which are based on management’s good faith expectations and beliefs concerning future developments. Actual results may differ materially from these expectations as a result of many factors. These factors include, but are not limited to, the risks and uncertainties described in the “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements” sections of the Company’s Annual Report on Form 10-K, filed on March 13, 2025, the Company's Quarterly Report on Form 10-Q, filed on May 13, 2025, and the Company's Quarterly Report on Form 10-Q, filed on August 7, 2025. The Company does not undertake any obligation to update such forward-looking statements. All market and industry data are based on Company estimates.
1


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 7, 2025
Intensity Therapeutics, Inc.
By:/s/ Lewis H. Bender
Name: Lewis H. Bender
Title:Chief Executive Officer
[Signature Page to the Form 8-K]
2

FAQ

Why is IQSTEL (IQST) increasing authorized shares to 26 million?

To cover reserved convertibles, potential Globetopper milestone shares, a planned $1 M stock swap with Cycurion, future M&A, financing and compensation needs.

How much could existing IQSTEL shareholders be diluted?

If the full authorization is ultimately issued, ownership could drop from 100 % to as little as 13.5 %, depending on pricing and allocation.

What are the key terms of the Cycurion (CYCU) stock exchange?

$1 M of stock each; IQST would issue 109,770 shares (3.04 % stake to CYCU) and receive 2,774,695 CYCU shares (5.86 % stake).

When will the share-increase amendment become effective?

Twenty calendar days after the information statement is mailed and the certificate is filed with the Nevada Secretary of State.

Are dissenter’s rights available for the amendment?

No. Nevada law does not grant appraisal rights for this type of share-authorization increase.

How many votes approved the amendment?

3,690,480 votes (51.68 % of total voting equity) were cast in favor via written consent on 31 July 2025.
INTENSITY THERAPEUTICS INC

NASDAQ:INTS

INTS Rankings

INTS Latest News

INTS Latest SEC Filings

INTS Stock Data

7.64M
19.84M
23.91%
10.08%
1.49%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SHELTON